Logo image of TBPH

THERAVANCE BIOPHARMA INC (TBPH) Stock Price, Quote, News and Overview

NASDAQ:TBPH - Nasdaq - KYG8807B1068 - Common Stock - Currency: USD

10.73  -0.22 (-2.01%)

After market: 10.73 0 (0%)

TBPH Quote, Performance and Key Statistics

THERAVANCE BIOPHARMA INC

NASDAQ:TBPH (6/10/2025, 5:20:00 PM)

After market: 10.73 0 (0%)

10.73

-0.22 (-2.01%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High11.82
52 Week Low7.44
Market Cap536.50M
Shares50.00M
Float47.58M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-04 2025-08-04
IPO05-16 2014-05-16


TBPH short term performance overview.The bars show the price performance of TBPH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10 15 20

TBPH long term performance overview.The bars show the price performance of TBPH in the last 1, 2 and 3 years. 1 year 2 years 3 years 5 10 15 20 25

The current stock price of TBPH is 10.73 USD. In the past month the price increased by 21.93%. In the past year, price increased by 26.53%.

THERAVANCE BIOPHARMA INC / TBPH Daily stock chart

TBPH Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 58.66 765.01B
JNJ JOHNSON & JOHNSON 15.57 376.43B
NVO NOVO-NORDISK A/S-SPONS ADR 22.1 352.49B
NVS NOVARTIS AG-SPONSORED ADR 14.27 234.21B
AZN ASTRAZENECA PLC-SPONS ADR 16.78 228.90B
MRK MERCK & CO. INC. 10.44 204.27B
PFE PFIZER INC 7.57 138.15B
SNY SANOFI-ADR 11.21 121.39B
BMY BRISTOL-MYERS SQUIBB CO 6.81 101.69B
GSK GSK PLC-SPON ADR 9.26 83.70B
ZTS ZOETIS INC 27.76 74.39B
HLN HALEON PLC-ADR 22.22 49.00B

About TBPH

Company Profile

TBPH logo image Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 97 full-time employees. The company went IPO on 2014-05-16. The firm operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.

Company Info

THERAVANCE BIOPHARMA INC

Ugland House, South Church Street

GEORGE TOWN GRAND CAYMAN KY1-1104 KY

CEO: Rick E Winningham

Employees: 97

TBPH Company Website

TBPH Investor Relations

Phone: 16508086000

THERAVANCE BIOPHARMA INC / TBPH FAQ

What is the stock price of THERAVANCE BIOPHARMA INC today?

The current stock price of TBPH is 10.73 USD. The price decreased by -2.01% in the last trading session.


What is the ticker symbol for THERAVANCE BIOPHARMA INC stock?

The exchange symbol of THERAVANCE BIOPHARMA INC is TBPH and it is listed on the Nasdaq exchange.


On which exchange is TBPH stock listed?

TBPH stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for THERAVANCE BIOPHARMA INC stock?

10 analysts have analysed TBPH and the average price target is 15.56 USD. This implies a price increase of 44.97% is expected in the next year compared to the current price of 10.73. Check the THERAVANCE BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is THERAVANCE BIOPHARMA INC worth?

THERAVANCE BIOPHARMA INC (TBPH) has a market capitalization of 536.50M USD. This makes TBPH a Small Cap stock.


How many employees does THERAVANCE BIOPHARMA INC have?

THERAVANCE BIOPHARMA INC (TBPH) currently has 97 employees.


What are the support and resistance levels for THERAVANCE BIOPHARMA INC (TBPH) stock?

THERAVANCE BIOPHARMA INC (TBPH) has a support level at 9.15 and a resistance level at 11.26. Check the full technical report for a detailed analysis of TBPH support and resistance levels.


Is THERAVANCE BIOPHARMA INC (TBPH) expected to grow?

The Revenue of THERAVANCE BIOPHARMA INC (TBPH) is expected to grow by 44.45% in the next year. Check the estimates tab for more information on the TBPH EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy THERAVANCE BIOPHARMA INC (TBPH) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does THERAVANCE BIOPHARMA INC (TBPH) stock pay dividends?

TBPH does not pay a dividend.


When does THERAVANCE BIOPHARMA INC (TBPH) report earnings?

THERAVANCE BIOPHARMA INC (TBPH) will report earnings on 2025-08-04.


What is the Price/Earnings (PE) ratio of THERAVANCE BIOPHARMA INC (TBPH)?

THERAVANCE BIOPHARMA INC (TBPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.12).


What is the Short Interest ratio of THERAVANCE BIOPHARMA INC (TBPH) stock?

The outstanding short interest for THERAVANCE BIOPHARMA INC (TBPH) is 8.47% of its float. Check the ownership tab for more information on the TBPH short interest.


TBPH Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to TBPH. When comparing the yearly performance of all stocks, TBPH is one of the better performing stocks in the market, outperforming 85.04% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

TBPH Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to TBPH. TBPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

TBPH Financial Highlights

Over the last trailing twelve months TBPH reported a non-GAAP Earnings per Share(EPS) of -1.12. The EPS decreased by -30.23% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -16.98%
ROE -35.14%
Debt/Equity 0.19
Chartmill High Growth Momentum
EPS Q2Q%-12.5%
Sales Q2Q%6.1%
EPS 1Y (TTM)-30.23%
Revenue 1Y (TTM)6.18%

TBPH Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to TBPH. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of 68.74% and a revenue growth 44.45% for TBPH


Ownership
Inst Owners94.28%
Ins Owners5.82%
Short Float %8.47%
Short Ratio14.16
Analysts
Analysts80
Price Target15.56 (45.01%)
EPS Next Y68.74%
Revenue Next Year44.45%